Targeting Tumor Angiogenesis with Histone Deacetylase Inhibitors

Overview

Journal Cancer Lett

Specialty Oncology

Date 2008 Dec 30

PMID 19111391

Citations 88

Authors

Leigh Ellis

Hans Hammers

Roberto Pili

Affiliations

Soon will be listed here.

Abstract

Solid tumor malignancies including breast, lung and prostate carcinomas are considered to be angiogenesis dependent. Tumor angiogenesis is often mediated by hypoxia secondary to tumor growth or by increased oncogenic signaling. Both mechanisms result in increased hypoxia-inducible factor-1 alpha (HIF-1alpha) signaling and its transcriptional target vascular endothelial growth factor (VEGF). Critical to HIF-1alpha signaling are post translational modifications including acetylation mediated by histone acetyltransferases (HATS) and deacetylation by histone deacetylases (HDACs). More recently, HDACs were shown to be up-regulated in response to hypoxia mediating increased HIF-1alpha signaling. HDAC inhibitors represent a new class of anti-cancer therapeutics which show great promise at inhibiting angiogenesis in pre-clinical animal models and early phase clinical trials. This review will discuss the role of HIF-1alpha and VEGF influence on tumor angiogenesis and how HDACs play a critical role in HIF-1alpha transcriptional activity. Furthermore it will also be discussed how targeting HDACs via their inhibition create new avenues in treating solid malignancies by increasing the activity of established and novel therapeutic applications.

Citing Articles

DNMT3A loss drives a HIF-1-dependent synthetic lethality to HDAC6 inhibition in non-small cell lung cancer.

Zhang J, Zhao Y, Liang R, Zhou X, Wang Z, Yang C Acta Pharm Sin B. 2025; 14(12):5219-5234.

PMID: 39807333 PMC: 11725086. DOI: 10.1016/j.apsb.2024.08.025.

Machine learning-based identification of histone deacetylase-associated prognostic factors and prognostic modeling for low-grade glioma.

Wen K, Zhu W, Luo Z, Wang W Discov Oncol. 2024; 15(1):824.

PMID: 39714729 PMC: 11666852. DOI: 10.1007/s12672-024-01713-7.

Histone deacetylase inhibitors for leukemia treatment: current status and future directions.

Hosseini M, Sanaat Z, Akbarzadeh M, Vaez-Gharamaleki Y, Akbarzadeh M Eur J Med Res. 2024; 29(1):514.

PMID: 39456044 PMC: 11515273. DOI: 10.1186/s40001-024-02108-8.

Inflammation mediated angiogenesis in chronic lymphocytic leukemia.

Mitrovic-Ajtic O, Zivkovic E, Suboticki T, Diklic M, dikic D, Vukotic M Ann Hematol. 2024; 103(8):2865-2875.

PMID: 38713255 DOI: 10.1007/s00277-024-05781-1.

Acetylation and Phosphorylation in the Regulation of Hypoxia-Inducible Factor Activities: Additional Options to Modulate Adaptations to Changes in Oxygen Levels.

Minisini M, Cricchi E, Brancolini C Life (Basel). 2024; 14(1).

PMID: 38276269 PMC: 10821055. DOI: 10.3390/life14010020.

References

Yu C, Friday B, Lai J, McCollum A, Atadja P, Roberts L . Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation. Clin Cancer Res. 2007; 13(4):1140-8. DOI: 10.1158/1078-0432.CCR-06-1751. View

Liu T, Kuljaca S, Tee A, Marshall G . Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat Rev. 2006; 32(3):157-65. DOI: 10.1016/j.ctrv.2005.12.006. View

Elson D, Thurston G, Huang L, Ginzinger D, McDonald D, Johnson R . Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1alpha. Genes Dev. 2001; 15(19):2520-32. PMC: 312791. DOI: 10.1101/gad.914801. View

Mottet D, Bellahcene A, Pirotte S, Waltregny D, Deroanne C, Lamour V . Histone deacetylase 7 silencing alters endothelial cell migration, a key step in angiogenesis. Circ Res. 2007; 101(12):1237-46. DOI: 10.1161/CIRCRESAHA.107.149377. View

Folkman J . Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285(21):1182-6. DOI: 10.1056/NEJM197111182852108. View

Saunders L, Verdin E . Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene. 2007; 26(37):5489-504. DOI: 10.1038/sj.onc.1210616. View

Kim M, Kwon H, Lee Y, Baek J, Jang J, Lee S . Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med. 2001; 7(4):437-43. DOI: 10.1038/86507. View

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu M . Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 2000; 60(6):1541-5. View

10.

Kim S, Jeong J, Park J, Lee J, Seo J, Jung B . Regulation of the HIF-1alpha stability by histone deacetylases. Oncol Rep. 2007; 17(3):647-51. View

11.

Zundel W, Schindler C, Koong A, Kaper F, Chen E, Gottschalk A . Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 2000; 14(4):391-6. PMC: 316386. View

12.

Faivre S, Demetri G, Sargent W, Raymond E . Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov. 2007; 6(9):734-45. DOI: 10.1038/nrd2380. View

13.

Rossig L, Li H, Fisslthaler B, Urbich C, Fleming I, Forstermann U . Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis. Circ Res. 2002; 91(9):837-44. DOI: 10.1161/01.res.0000037983.07158.b1. View

14.

Quintero M, MacKenzie N, Brennan P . Hypoxia-inducible factor 1 (HIF-1) in cancer. Eur J Surg Oncol. 2004; 30(5):465-8. DOI: 10.1016/j.ejso.2004.03.008. View

15.

Kwon H, Kim M, Kim M, Nakajima H, Kim K . Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int J Cancer. 2002; 97(3):290-6. DOI: 10.1002/ijc.1602. View

16.

SALCEDA S, Caro J . Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem. 1997; 272(36):22642-7. DOI: 10.1074/jbc.272.36.22642. View

17.

Weidemann A, Johnson R . Biology of HIF-1alpha. Cell Death Differ. 2008; 15(4):621-7. DOI: 10.1038/cdd.2008.12. View

18.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335-42. DOI: 10.1056/NEJMoa032691. View

19.

Huang L, Arany Z, Livingston D, BUNN H . Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem. 1996; 271(50):32253-9. DOI: 10.1074/jbc.271.50.32253. View

20.

Sandler A, Gray R, Perry M, Brahmer J, Schiller J, Dowlati A . Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355(24):2542-50. DOI: 10.1056/NEJMoa061884. View